Evidence map›Paper›PMID 39688904›Full record

ArticleeLife2024

Targeted anticancer pre-vinylsulfone covalent inhibitors of carbonic anhydrase IX.

Aivaras Vaškevičius, Denis Baronas, Janis Leitans, Agnė Kvietkauskaitė, Audronė Rukšėnaitė, Elena Manakova, Zigmantas Toleikis, Algirdas Kaupinis, Andris Kazaks, Marius Gedgaudas and 12 more

Abstract read
In one paragraph

Article in eLife, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Di-Journal of medicinal chemistry · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Aivaras VaškevičiusDepartment of Biothermodynamics and Drug Design, Institute of Biotechnology, Life Sciences Center, Vilnius University, Vilnius, Lithuania.ORCID https://orcid.org/0009-0006-8202-9748
Denis BaronasDepartment of Biothermodynamics and Drug Design, Institute of Biotechnology, Life Sciences Center, Vilnius University, Vilnius, Lithuania.ORCID https://orcid.org/0000-0003-1878-0837
Janis LeitansLatvian Biomedical Research and Study Centre, Riga, Latvia.
Agnė KvietkauskaitėDepartment of Biothermodynamics and Drug Design, Institute of Biotechnology, Life Sciences Center, Vilnius University, Vilnius, Lithuania.
Audronė RukšėnaitėDepartment of Biological DNA Modification, Institute of Biotechnology, Life Sciences Center, Vilnius University, Vilnius, Lithuania.
Elena ManakovaDepartment of Protein - DNA Interactions, Institute of Biotechnology, Life Sciences Center, Vilnius University, Vilnius, Lithuania.
Zigmantas ToleikisSector of Biocatalysis, Institute of Biotechnology, Life Sciences Center, Vilnius University, Vilnius, Lithuania.
Algirdas KaupinisProteomics Center, Institute of Biochemistry, Life Sciences Center, Vilnius University, Vilnius, Lithuania.
Andris KazaksLatvian Biomedical Research and Study Centre, Riga, Latvia.
Marius GedgaudasDepartment of Biothermodynamics and Drug Design, Institute of Biotechnology, Life Sciences Center, Vilnius University, Vilnius, Lithuania.
Aurelija MickevičiūtėDepartment of Biothermodynamics and Drug Design, Institute of Biotechnology, Life Sciences Center, Vilnius University, Vilnius, Lithuania.
Vaida JuozapaitienėDepartment of Biothermodynamics and Drug Design, Institute of Biotechnology, Life Sciences Center, Vilnius University, Vilnius, Lithuania.
Helgi B SchiöthFunctional Pharmacology and Neuroscience, Department of Surgical Sciences, Uppsala University, Uppsala, Sweden.
Kristaps JaudzemsLatvian Institute of Organic Synthesis, Riga, Latvia.
Mindaugas ValiusProteomics Center, Institute of Biochemistry, Life Sciences Center, Vilnius University, Vilnius, Lithuania.
Kaspars TarsLatvian Biomedical Research and Study Centre, Riga, Latvia.
Saulius GražulisSector of Crystallography and Chemical Informatics, Institute of Biotechnology, Life Sciences Center, Vilnius University, Vilnius, Lithuania.
Franz-Josef Meyer-AlmesDepartment of Chemical Engineering and Biotechnology, University of Applied Sciences Darmstadt, Darmstadt, Germany.ORCID https://orcid.org/0000-0002-1001-3249
Jurgita MatulienėDepartment of Biothermodynamics and Drug Design, Institute of Biotechnology, Life Sciences Center, Vilnius University, Vilnius, Lithuania.
Asta ZubrienėDepartment of Biothermodynamics and Drug Design, Institute of Biotechnology, Life Sciences Center, Vilnius University, Vilnius, Lithuania.
Virginija DudutienėDepartment of Biothermodynamics and Drug Design, Institute of Biotechnology, Life Sciences Center, Vilnius University, Vilnius, Lithuania.
Daumantas MatulisDepartment of Biothermodynamics and Drug Design, Institute of Biotechnology, Life Sciences Center, Vilnius University, Vilnius, Lithuania.ORCID https://orcid.org/0000-0002-6178-6276

Funding

EU Recovery and Resilience Mechanim 5.2.1.1.i.0/2/24/I/CFLA/001Research Council of Lithuania S-MIP-22-35
6 · The paper itself

Abstract

We designed novel pre-drug compounds that transform into an active form that covalently modifies particular His residue in the active site, a difficult task to achieve, and applied to carbonic anhydrase (CAIX), a transmembrane protein, highly overexpressed in hypoxic solid tumors, important for cancer cell survival and proliferation because it acidifies tumor microenvironment helping invasion and metastases processes. The designed compounds have several functionalities: (1) primary sulfonamide group recognizing carbonic anhydrases (CA), (2) high-affinity moieties specifically recognizing CAIX among all CA isozymes, and (3) forming a covalent bond with the His64 residue. Such targeted covalent compounds possess both high initial affinity and selectivity for the disease target protein followed by complete irreversible inactivation of the protein via covalent modification. Our designed prodrug candidates bearing moderately active pre-vinylsulfone esters or weakly active carbamates optimized for mild covalent modification activity to avoid toxic non-specific modifications and selectively target CAIX. The lead inhibitors reached 2 pM affinity, the highest among known CAIX inhibitors. The strategy could be used for any disease drug target protein bearing a His residue in the vicinity of the active site.

Indexed as

Antineoplastic AgentsCarbonic Anhydrase InhibitorsCarbonic Anhydrase IXSulfonesAntigens, NeoplasmHumansAntigens, NeoplasmAntineoplastic AgentsCA9 protein, humanCarbonic Anhydrase InhibitorsCarbonic Anhydrase IXdivinyl sulfoneSulfonescarbonic anhydrase IXfluorescent thermal shift assaymolecular biophysicsnonestructural biologysulfonamidetargeted covalent inhibitorsvinylsulfoneX-ray crystallography

Identifiers

PMID39688904
PMCPMC11651660

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.